Ratings Pacific Biosciences of California, Inc. Deutsche Boerse AG

Equities

P09

US69404D1081

Real-time Estimate Tradegate Other stock markets 08:33:55 2024-06-18 EDT			5-day change	1st Jan Change
1.594 ^EUR	+6.64%		-6.01%	-80.95%

06-10	PacBio and International Research Consortium Colors Announce Release of First-Ever HiFi Long-Read Variant Database	CI
06-03	Jefferies & Co Initiates Coverage on Pacific Biosciences of California With Buy Rating, $4 Price Target	MT

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
The company's share price in relation to its net book value makes it look relatively cheap.
For several months, analysts have been revising their EPS estimates roughly upwards.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
With an enterprise value anticipated at 4.91 times the sales for the current fiscal year, the company turns out to be overvalued.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
Over the past four months, analysts' average price target has been revised downwards significantly.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.	-80.95%	455M	-
THERMO FISHER SCIENTIFIC	+7.01%	217B	B
DANAHER CORPORATION	+9.85%	188B	B-
INTUITIVE SURGICAL, INC.	+27.51%	153B	B-
BOSTON SCIENTIFIC CORPORATION	+31.79%	112B	A-
SIEMENS HEALTHINEERS AG	-0.84%	62.84B	A-
EDWARDS LIFESCIENCES CORPORATION	+13.93%	52.35B	B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+1.85%	49.33B	B+
GE HEALTHCARE TECHNOLOGIES INC.	+0.30%	35.4B	-
RESMED, INC.	+22.28%	30.9B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes